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Activation of the Lectin Pathway of Complement in
Pig-to-Human Xenotransplantation Models
Anjan K. Bongoni,1,2,3 David Kiermeir,3 Hansjörg Jenni,4 Annegret Wünsch,5 Andrea Bähr,5
David Ayares,6 Jörg D. Seebach,7 Eckhard Wolf,5 Nikolai Klymiuk,5 Mihai A. Constantinescu,3
Esther Vögelin,3 and Robert Rieben1,3,8
Background. Natural IgM containing anti-Gal antibodies initiates classic pathway complement activation in xenotrans-
plantation. However, in ischemia-reperfusion injury, IgM also induces lectin pathway activation. The present study was
therefore focused on lectin pathway as well as interaction of IgM and mannose-binding lectin (MBL) in pig-to-human
xenotransplantation models.
Methods. Activation of the different complement pathways was assessed by cell enzyme-linked immunosorbent assay
using human serum on wild-type (WT) and >-galactosyl transferase knockout (GalTKO)/hCD46-transgenic porcine
aortic endothelial cells (PAEC). Colocalization of MBL/MASP2 with IgM, C3b/c, C4b/c, and C6 was investigated by
immunofluorescence in vitro on PAEC and ex vivo in pig leg xenoperfusion with human blood. Influence of IgM on MBL
binding to PAEC was tested using IgM depleted/repleted and anti-Gal immunoabsorbed serum.
Results. Activation of all the three complement pathways was observed in vitro as indicated by IgM, C1q, MBL, and
factor Bb deposition on WT PAEC. MBL deposition colocalized with MASP2 (Manders’ coefficient [3D] r2=0.93),
C3b/c (r2=0.84), C4b/c (r2=0.86), and C6 (r2=0.80). IgM colocalized with MBL (r2=0.87) and MASP2 (r2=0.83).
Human IgM led to dose-dependently increased deposition of MBL, C3b/c, and C6 on WT PAEC. Colocalization of
MBL with IgM (Pearson’s coefficient [2D] rp
2=0.88), C3b/c (rp
2=0.82), C4b/c (rp
2=0.63), and C6 (rp
2=0.81) was also
seen in ex vivo xenoperfusion. Significantly reduced MBL deposition and complement activation was observed on
GalTKO/hCD46-PAEC.
Conclusion. Colocalization of MBL/MASP2 with IgM and complement suggests that the lectin pathway is activated
by human anti-Gal IgM and may play a pathophysiologic role in pig-to-human xenotransplantation.
Keywords: Mannose-binding lectin, Complement pathways, Natural antibody, Xenotransplantation,
Porcine aortic endothelial cells.
(Transplantation 2013;96: 791Y799)
The use of xenografts of pig origin may significantlyexpand the pool of available donor organs for humans
(1, 2). However, the major obstacle of pig-to-human
xenotransplantation is that grafts are subjected to potent
xenorejection processes (3). Hyperacute rejection is the
first and most destructive mechanism (4, 5), characterized
by rapid loss of graft function after connecting to the host
circulation. It is a consequence of the binding of human
preformed xenoreactive antibodies against the disaccharide
Gal>1-3Gal expressed on porcine endothelium (reviewed
in Ref. (6)). This antigen-antibody interaction activates the
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complement cascade on the endothelial cell membrane,
leading to endothelial cell activation and damage, intra-
vascular graft thrombosis, and vessel occlusion (7).
The complement system is activated via three well-
characterized pathwaysVthe classic, the alternative, and
the lectin pathways. Each of them has its own mechanism
of activation, resulting in activation of C3, followed by
generation of the membrane attack complex (8). In hyperacute
rejection, xenoreactive antibody-mediated activation of the
classic pathway is commonly accepted as the main comple-
ment activation pathway (9, 10). By amplifying the generation
of C3b, the alternative pathway also becomes critical in xeno-
graft rejection. However, currently available data do not answer
the question whether the lectin pathway may also be involved
in the initiation of xenorejection.
The lectin pathway is initiated by interactions between
mannose-binding lectin (MBL) and certain carbohydrate
arrays (11). MBL naturally exists in a complex with MBL-
associated serine proteases (MASPs) (12, 13). When MBL
binds to a target, the MASPs are activated (14) and cleave
their respective substratesVC4 and C2 for MASP2 and C3
and C2 for MASP1 (15). Historically, the lectin pathway of
complement activation is known as antibody-independent
pathway. However, several studies using animal models of
ischemia-reperfusion injury demonstrated that MBL also
interacts with immune complexes to activate complement
via the lectin pathway (16Y18). In addition, a recent in vitro
study suggested that 20% of human serum IgM could bind
to immobilized human MBL (19, 20).
In a bypass activation pathway, MBL can directly acti-
vate C3 and the alternative pathway of complement, which are
independent of C2 (21). In addition, MBL binding to poly-
meric IgA induces the initiation of lectin pathway of com-
plement activation (22). Furthermore, myocardial and skeletal
ischemia-reperfusion injury studies demonstrated that com-
plement activation and resulting C3 deposition are mediated
by IgM and MBL (23, 24) and independent of C1q and
the classic pathway (24). Taken together, these observations
extend the idea that activation of the lectin pathway of
complement may not be completely antibody independent.
Thus far, the role of the lectin pathway of complement
has not been looked at in xenotransplantation. The present
study was therefore focused on lectin pathway activation
in pig-to-human xenotransplantation. In particular, we in-
vestigated the interaction of MBL and IgM in pig-to-human
in vitro as well as ex vivo xenotransplantation models.
RESULTS
Complement Pathways Involved in Pig-to-Human
Xenorejection In Vitro (PAEC Treated with NHS)
Deposition of C1q (classic pathway), MBL (lectin
pathway), and factor Bb (alternative pathway) on porcine
aortic endothelial cells (PAEC) was assessed by cell enzyme-
linked immunosorbent assay (ELISA). Wild-type (WT) PAEC
exposed to 1:2 diluted normal human serum (NHS) showed
deposition of IgM, C1q, MBL, factor Bb, C3b/c, C4b/c, and
C5b-9 (Fig. 1A). In addition, MBL, C3b/c, and C6 deposition
was shown on PAEC treated with 1:10 diluted, MBL-deficient,
or C1q-depleted serum or NHS (Fig. 1B). Incubation of WT
PAEC with MBL-deficient or C1q-depleted serum also led to
expression of adhesion molecules (VCAM-1 and CD62E;
Fig. 1C) as well as PAEC cytotoxicity (Fig. 1D).
Lectin Pathway Complement Activation
In VitroVColocalization Analysis
Immunofluorescence (IF) staining was performed on
WT PAEC treated with 1:10 diluted NHS for the colocalized
deposition of MBL with complement proteins. Deposition
of MBL on WT PAEC was colocalized with MASP2, C3b/c,
C4b/c, and C6, suggesting activation of the lectin pathway in
this xenotransplantation setting (Fig. 2).
Quantitative colocalization analysis was performed by
Manders’ correlation coefficient (Rm) using z-stack confocal
images and Imaris software version 7.2.3 (Bitplane). A total
overlap of both fluorescent color channels, indicating a per-
fect three-dimensional colocalization, is indicated by ‘‘Rm=1,’’
and no colocalization by ‘‘Rm=0.’’ The Manders’ correlation
coefficient values were 0.93 for MBL-MASP2, 0.84 for MBL-
C3b/c, 0.86 for MBL-C4b/c, and 0.80 for MBL-C6, suggesting
an important contribution of MBL for total complement
deposition in this model.
Colocalization of IgM and MBL/MASP2
on WT PAEC
Colocalization of natural IgM with MBL and MASP2
was investigated on NHS-treated PAEC by confocal micros-
copy. Colocalized deposition of IgM with MBL and MASP2
was observed on PAEC (yellow staining) (Fig. 3). Manders’
colocalization analysis showed near-perfect IgM colocalization
with MBL (Rm=0.87) and MASP2 (Rm=0.83).
IgM-Dependent MBL and Complement
Deposition on WT PAEC
Binding of MBL to the major porcine xenoantigen Gal>1-
3Gal on WT PAEC was assessed in anti-Gal immunoabsorbed
and immunoglobulin-depleted (Ig-depleted) serum, respec-
tively. Compared with NHS, reduced MBL deposition was
observed on PAEC when incubated with anti-Gal immu-
noabsorbed NHS or Ig-depleted serum. Purified polyclonal
human IgM was used to replete anti-Gal immunoabsorbed
NHS and Ig-depleted serum, respectively, which resulted
in dose-dependently increased deposition of MBL, C3b/c,
and C6 on PAEC (Fig. 3C,D). In addition, WT PAEC were
treated with purified human polyclonal IgM followed by
incubation with purified MBL protein, resulting in a dose-
dependently increased binding of purified MBL to PAEC
(Fig. 3D).
Complement Regulation by GalTKO/
hCD46 PAEC
WT or >-galactosyl transferase knockout (GalTKO)/
hCD46 PAEC were treated with 1:10 diluted NHS and as-
sessed for complement deposition as well as complement-
mediated PAEC activation and cytotoxicity. Absence of
Gal epitopes and overexpression of hCD46 (Fig. 4) signifi-
cantly reduced binding of IgM, C1q, MBL, and downstream
complement proteins on GalTKO/hCD46 PAEC compared
with WT (Fig. 4D). This reduced complement activation on
the genetically modified PAEC correlated well with reduced
complement-mediated cytotoxicity (Fig. 4E). These observa-
tions were also confirmed by IF/confocal microscopy using
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WT and GalTKO/hCD46 PAEC treated with 1:10 diluted
NHS (Fig. 4F).
Analysis of Lectin Pathway Complement Activation
during Ex Vivo Pig Limb Xenoperfusion
Extracorporeal perfusion of WT porcine forelimbs with
heparin anticoagulated human blood did not reveal signs
of hyperacute rejection and lasted for at least 12 hr, after
which it had to be terminated due to continuous small blood
losses. Blood gas analysis showed constant physiologic po-
tassium, lactate (10.78T0.63), and pH values (7.32T0.06). All
limbs showed full muscular response on neural stimulation
throughout the experiments. Stable and physiologic hemo-
dynamic perfusion parameters (pressure, flow) could be
maintained throughout all perfusions. To prevent blood loss
due to bleeding, biopsy samples were collected only at later
time points of perfusion, except for one experiment where
samples were collected 1 hr after the onset of perfusion. These
biopsy samples were used to analyze deposition of MBL, C1q,
and factor Bb (Fig. 5AYC).
Tissue samples taken after 12 hr perfusion were stained
for deposition of human IgM, MBL, C3b/c, C4b/c, and C6.
Analysis by fluorescence microscopy revealed that IgM, C3b/c,
C4b/c, and C6 were codeposited with human MBL in the
tissue. Quantitative two-dimensional colocalization analysis
was performed by Pearson’s correlation coefficient (Rp) using
fluorescence microscopy images and Imaris software. A total
overlap of both fluorescent color channels, represented as
‘‘Rp=+1,’’ indicates a perfect colocalization, ‘‘Rp=0’’ random
colocalization, and ‘‘Rp=j1’’ perfect exclusion. The Rp
values were 0.88 for IgM-MBL, 0.82 for C3b/c-MBL, 0.63
for C4b/c-MBL, and 0.81 for C6-MBL (Fig. 5DYS).
DISCUSSION
The role of complement activation in the pathogenesis
of pig-to-human xenograft rejection is well established.
However, almost nothing is known to date about the activa-
tion of the lectin pathway of complement in xenorejection.
We demonstrate here for the first time that all three pathways
of complement are activated in a model of pig-to-human
xenotransplantation. We could show full activation of com-
plement, including formation of the terminal complement
complex and complement-mediated cytotoxicity also in the
absence of C1q. In addition, our data indicate that activa-
tion of the MBL route of complement is dependent on IgM,
both in vitro and ex vivo, in a pig-to-human xenotransplan-
tation model.
FIGURE 1. Cell ELISA, activation of classic, lectin, and alternative complement pathways in a pig-to-human in vitro xeno-
transplantation model. A, WT PAEC were treated with 1:2 diluted NHS at 37-C for 45 min and the deposition of human IgM as
well as complement proteins was assessed by specific antibodies. B, treatment of PAEC with 1:10 diluted NHS, MBL-deficient
serum and C1q-depleted serum, respectively, and assessment of deposition of C1q, MBL, factor Bb, C3b/c, and C6. C,
prolonged incubation (4 hr at 37-C) of PAECwith NHS/C1q-depleted serum/MBL-deficient serum (1:10) and assessment of the
expression of adhesion molecules VCAM-1 and CD62E. D, treatment of PAEC with 1:10 diluted NHS/C1q-depleted serum/
MBL-deficient serum for 120 min at 37-C and assessment of cytotoxicity by calcein AM and EthD-1. Significance was tested
using one-way calcein AM with Bonferroni correction (*PG0.05, **PG0.01, ***PG0.001). Data are meanTSD of three inde-
pendent experiments.
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Endothelium is the first cell type to make contact with
the recipients’ blood in xenotransplantation or xenoperfusion.
We therefore chose to analyze the effects of human serum
on PAEC in vitro to perfuse porcine limbs ex vivo with
whole, heparin-anticoagulated human blood. PAEC treated
with NHS showed deposition of MBL, C1q, and factor Bb on
their surface, indicating that all three pathways are involved
in complement-mediated xenograft damage. In addition, de-
position of C4b/c, C3b/c, C6, and C5b-9, detected as C9
neoepitope, were also observed on NHS-treated PAEC. The
same markers, indicating full activation of complement, were
also found when C1q-depleted serum was used. Furthermore,
C1q-depleted serum induced PAEC activation, as measured by
expression of the adhesion molecules E-selectin and VCAM-1,
as well as PAEC cytotoxicity in a complement-dependent
manner.
Binding of MBL was colocalized with C3b/c, C4b/c, and
C6 on PAEC, suggesting that deposition of MBL on the cells
plays a functional role in complement activation. Because
natural antibodies are the major contributors to complement
activation, the involvement of IgM in lectin pathway activa-
tion was then investigated. Colocalization studies on PAEC
treated with NHS revealed that MBL/MASP2 deposition was
colocalized with IgM, quantitative Manders’ coefficient values
indicating a near 100% colocalization, suggesting that IgM
and MBL may work together in a synergetic way. The im-
portance of anti-Gal IgM in lectin pathway activation was
further confirmed by depletion of anti-Gal antibodies from
NHS by immunoabsorption, which led to a significantly
reduced binding of IgM as well as MBL on PAEC and also to
a reduction of C5b-9 deposition. Repletion of immu-
noabsorbed or total Ig-depleted serum with polyclonal
human IgM resulted in a dose-dependently increased de-
position of IgM, MBL, and further downstream comple-
ment components. In addition, a dose-dependent deposition
of purified MBL was found on PAEC treated with human
polyclonal IgM. Taken together, these data indicate that the
activation of the lectin pathway of complement in this xeno-
transplantation model is dependent on IgM binding to the
target cells. This finding is in line with a recent study showing
MBL binding sites on IgM, containing mainly GlcNAc-
terminated glycans, which are strong ligands for MBL (20).
Also, the oligomannose structures present on IgM at Asn-402
and Asn-563 could provide binding sites for MBL (25, 26).
Knockout of the Gal epitope in pigs is currently being
combined with overexpression of human complement regu-
latory proteins such as hCD46 to prevent pig-to-human xe-
nograft rejection. In this study, PAEC from GalTKO/hCD46
FIGURE 2. Colocalization analysis ofMBLwith other complement proteins. NHS (1:10) treatedWTPAECwere stained for the
deposition of MBL (red fluorescence) and MASP2, C3b/c, C4b/c, and C6, respectively (green fluorescence). Representative
colocalization images ofMBL with the respectiveManders’ correlation coefficients are shown: (A) MASP2 (Rm=0.93), (B) C3b/c
(Rm=0.84), (C) C4b/c (Rm=0.86), and (D) C6 (Rm=0.80). Colocalization was quantified by z-series analysis using Manders’
correlation coefficient. For MBL-C6 colocalization (D), also side views are shown as z-panels to the right and below the image.
794 www.transplantjournal.com Transplantation & Volume 96, Number 9, November 15, 2013
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
pigs showed significantly reduced deposition of MBL and
complement proteins as well as no cytotoxicity when treated
with NHS. These observations suggest that GalTKO and ex-
pression hCD46 could also help to prevent lectin pathway
activation during pig-to-human xenotransplantation.
Tissue samples from porcine forelimbs ex vivo xeno-
perfused with whole, heparin-anticoagulated human blood
were analyzed for the involvement of IgM-mediated lectin
pathway activation. Deposition of MBL, C1q, and factor Bb was
observed on 1 hr perfusion samples, suggesting that all three
pathways of complement are activated. In addition, MBL was
colocalized with IgM in 12 hr perfusion samples and the find-
ing of colocalized deposition of MBL with C3, C4, and C6 in-
dicates that also in ex vivo xenoperfusion the MBL route of
complement is functional, confirming the in vitro data.
In conclusion, our results demonstrate activation and
pathogenic role of the lectin pathway of complement in
xenotransplantation. Colocalized deposition of IgM with
MBL and MASP2 indicates that activation of the lectin
pathway of complement in this pig-to-human xenotrans-
plantation model is dependent on IgM.
MATERIALS AND METHODS
Cell ELISA and Determination of Complement
Activation Pathways in Xenotransplantation
A modified whole-cell ELISA was used to detect the complement pathways
involved in xenotransplantation, similar to methods described previously
(27, 28). WT PAEC as well as GalTKO/hCD46 transgenic PAEC were grown
to confluence in 96-well plates and washed twice with ELISA wash buffer
supplemented with or without calcium (45 mM NaCl, 10 mM HEPES,
680 mM CaCl2, and 490 mM MgCl2). Pooled NHS or alternatively C1q-
depleted serum (A509; Quidel, Darmstadt, Germany) or MBL-deficient
serum (HSR002; Statens Serum Institut, Copenhagen, Denmark) in GVB++
(1:2 or 1:10) was added to the cells and incubated at 37-C followed by washing
with ELISA wash buffer. Cells were fixed in 1% paraformaldehyde for 15 min
at room temperature (RT), washed, and blocked with phosphate-buffered
saline (PBS)/1% bovine serum albumin (BSA) for 90 min at RT. Goat anti-
human IgM (fluorescein isothiocyanate [FITC] labeled; catalog number
F5384; Dako, Carpinteria, CA), rabbit anti-human C1q (A0136; Dako), mouse
anti-human MBL (clone 15C5; sc80598; Santa Cruz Biotechnology, Santa
Cruz, CA), rabbit anti-human factor Bb (ab72658; Abcam, Cambridge, UK),
rabbit anti-human C3b/c (FITC labeled; A0062; Dako), rabbit anti-human
C4b/c (FITC labeled; F0169; Dako), mouse anti-human C5b-9 (aE11; 5010;
Diatec, Oslo, Norway), mouse anti-human CD62E (LS-C13922; LifeSpan,
FIGURE 3. Role of IgM in the activation of lectin pathway. Colocalization (yellow) of IgM (green) with MBL and MASP2
(red), respectively. Representative colocalization images of IgM with the respective Manders’ correlation coefficients are
shown: (A) IgM-MBL (Rm=0.87) and (B) IgM-MASP2 (Rm=0.83) on NHS-treated WT PAEC. For IgM-MASP2 colocalization (B),
also side views are shown as z-panels to the right and below the image. IgM-dependent MBL and complement deposition
on PAEC. Deposition of MBL and complement components on PAEC was tested in the absence (anti-Gal immunoabsorbed
NHS/Ig-depleted serum) or presence of anti-Gal IgM (repletion with polyclonal human IgM). C, deposition of IgM, C1q,
MBL, C3b/c, and C6 on PAEC incubated with Ig-depleted serum repleted with increasing concentrations of purified human
IgM as well as NHS. D, binding of MBL to PAEC in the presence anti-Gal immunoabsorbed NHS (1:10) or purified MBL at a
fixed concentration (1.15 Kg/mL). MBL-binding curves for addition of increasing concentrations of purified human IgM are
shown. Data are meanTSD of three independent experiments.
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Seattle, WA), mouse anti-human VCAM-1 (1G11B1; 9510; Southern Biotech,
Birmingham, AL), mouse anti->Gal (4F10; a gift of A. Bendelac, Howard
Hughes Medical Institute [Chevy Chase, MD] and University of Chicago
[Chicago, IL]), and mouse anti-human CD46 (HM2103; Hycult Biotech,
Plymouth Meeting, PA) were diluted in PBS/1% BSA and incubated for
1 hr at RT followed by three washes. Subsequently, biotin-conjugated goat
anti-mouse IgG (ab6788; Abcam) or goat anti-rabbit Ig (E0432; Dako)
were used, diluted 1:500 in PBS/1% BSA, and incubated for 1 hr at RT.
After washing, alkaline phosphataseYconjugated rabbit anti-FITC (ab49368;
Abcam) or streptavidinYalkaline phosphatase (RPN1234V; GE Healthcare,
Cleveland, OH) diluted 1:1000 in PBS/1% BSA was incubated for 30 min at
RT. After washing, 1 mg/mL p-nitrophenyl phosphate substrate (Sigma, St.
Louis, MO) was added. Color development was quantified at 405 nm (refer-
ence 490 nm; Infinite M1000 microplate reader; Tecan, Männedorf,
Switzerland).
Complement-Mediated PAEC cytotoxicity
Complement-induced PAEC cytotoxicity was measured by calcein AM/
ethidium homodimer-1 (EthD-1) staining. A Live/Dead Kit (Molecular
Probes, Eugene, OR) was used and protocols provided by the manufacturer
FIGURE 4. Regulation of complement activation on PAEC using genetic modification strategies. (A) Gal epitope and
(B and C) hCD46 expression on WT and GalTKO/hCD46 PAEC analyzed by cell ELISA and IF staining. D, deposition of
IgM, C1q, MBL, C3b/c, C4b/c, and C5b-9 on NHS (1:10)Ytreated WT and GalTKO/hCD46 PAEC. E, treatment of PAEC with
1:10 diluted NHS for 120 min at 37-C and assessment of cytotoxicity by calcein AM and EthD-1. F, confocal analysis of IgM,
C1q, MBL, C4b/c, C3b/c, and C5b-9 onWT and GalTKO/hCD46 PAEC treated with 1:10 diluted NHS. Significance was tested
using one-way analysis of variance with Bonferroni correction (*PG0.05, **PG0.01, ***PG0.001). Data are meanTSD of three
independent experiments. Scale bars, 30 Km.
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were adopted. Briefly, confluent WT and GalTKO/hCD46 PAEC in a 96-well
plate were exposed to 1:10 diluted NHS, C1q-depleted or MBL-deficient
serum, for 120 min at 37-C. After washing with PBS, 100 KL of 1 KM
calcein AM and 2 KM EthD-1 was added to the cells and incubated in dark
for 15 min. The fluorescence excitation and emissions of calcein AM and
EthD-1 were acquired at 485/535 and 530/635 nm, respectively, using the
Infinite M1000 microplate reader (Tecan).
IF Staining
Activation of the lectin pathway of complement was further investigated
by immunofluorescence staining using confocal microscopy. Briefly, WT
and GalTKO/hCD46 PAEC grown to confluence on eight-well Lab-Tek
chamber slides (Milian) were washed twice with PBS++ (PBS containing
1 mM CaCl2 and 1 mM MgCl2) and treated with 1:10 dilution NHS for 45 to
60 min at RT. Slides were washed thrice and fixed with parapicric acid for
15 min at RT. After washing and blocking with PBS/3% BSA for 30 min at RT,
slides were incubated for 60 min with primary antibodies for the following
antigens: IgM (FITC labeled; F5380; Sigma), MBL (15C5; Santa Cruz Bio-
technology), MASP2 (sc-17905; Santa Cruz Biotechnology), C4b/c-FITC
(Dako), C3b/c-FITC (Dako), and C6 (A307; Quidel) diluted in PBS/1% BSA.
After washing, fluorescence-labeled specific secondary antibodies diluted in
FIGURE 5. Colocalization of MBL with IgM and complement in an ex vivo xenoperfusion model. Tissue samples from
ex vivo xenoperfused pig limbs with heparinized, whole human blood for 1 hr were assessed for deposition of (A) MBL,
(B) C1q, and (C) factor Bb. Biopsy samples of 12 hr perfusion were analyzed for IgM-mediated lectin pathway activation by
using immunofluorescence staining. DYG, deposition of MBL (red), IgM (green), and codeposition (yellow). HYK, deposition
of MBL (red), C3b/c (green), and codeposition (yellow). LYO, Deposition of MBL (red), C4b/c (green), and codeposition
(yellow). PYS, deposition of MBL (red), C6 (green), and codeposition (yellow). D, H, L, and P, 4¶,6-diamidino-2-phenylindole
staining of nuclei. The Rp values represent Pearson’s colocalization coefficient. Representative images of six independent
experiments are shown. Scale bars, 100 Km.
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PBS/1% BSA were incubated for 60 min and the slides were mounted with
glycergel (C0563; Dako). The stained slides were then analyzed using a Zeiss
LSM5 confocal laser scanning microscope.
Immunoabsorption of Human Serum on
PAA-Bdi Sepharose
To investigate the importance of anti-Gal>1-3Gal IgM for MBL binding
to PAEC, immunoabsorption of NHS was carried out to eliminate anti-Gal
antibodies from NHS. Conjugates of the B-disaccharide Gal>1-3Gal (Bdi) and
poly-N-hydroxyethylacrylamide (PAA-Bdi), covalently linked to Sepharose 6FF
(PAA-Bdi Sepharose), were obtained from Dr. Nicolai Bovin (Moscow, Russia).
Mini-spin columns were packed with 100 or 200 KL PAA-Bdi Sepharose and
rinsed with PBS (10Y15 min, 200 rpm, 0-C). NHS (450 KL) was absorbed over
the columns. Thereafter, immunoabsorbed NHS aliquots were prepared and
stored at j80-C until use.
Role of IgM on MBL Binding to PAEC
The influence of IgM on binding of MBL to PAEC was investigated by cell
ELISA using immunoabsorbed NHS and Ig-depleted serum (SunnyLab, Kent,
UK). Human polyclonal IgM (A50168H; Meridian Life Science, Cincinnati,
OH) was used to replete immunoabsorbed NHS/Ig-depleted serum. Binding
of purified MBL (HSR008; Statens Serum Institut) on PAEC in the presence
of human polyclonal IgM was also tested.
Ex vivo Xenoperfusion of Pig Limbs with Whole,
Anticoagulated Human Blood
Six forelimbs of WT pigs were used to perfuse with whole, heparin-
anticoagulated human blood (29, 30). Large white pigs were premedicated
and anesthetized with ketamine, xylazine, midazolam, and atropine and
mechanically ventilated (O2/air 1:3, isoflurane 1Y1.5 vol.%). Forelimbs were
amputated by dissection of the shoulder girdle muscles using an electrocautery
device (ICC 350; ERBE Elektromedizin, Tübingen, Germany). The neuro-
vascular bundle in the axillar region was laid open and two veins and one
artery of the amputated forelimb were cannulated using 10 French cannulas.
All animal experiments were conducted in compliance with the Guide for the
Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised
1996) and Swiss national guidelines. The study was approved by the local
animal experimentation committee of the Canton of Bern.
Five hundred milliliters of blood each were withdrawn from individual
human donors into standard transfusion bags to which 10,000 IU heparin
were added. The porcine forelimbs were attached to extracorporeal perfu-
sion circuits as described previously (29). Xenogeneic perfusion of the
porcine limbs was then performed with the whole, heparin-anticoagulated
human blood. The perfusion parameters (arterial blood gas, response to
nerve stimulation, etc.) were monitored throughout the experiment.
Skeletal muscle biopsies were collected before perfusion from the con-
tralateral extremity as baseline samples. Different time-point biopsies were
collected after 1 hr (n=1) and 12 hr (n=6) of perfusions. Samples were fixed
in 2% buffered formaldehyde solution for 24 hr and then transferred into
18% sucrose for 15 hr. Then, the samples were embedded in Shandon M1
embedding matrix (Thermo Scientific, Waltham, MA) and stored at j20-C
until sectioned.
IF Staining for IgM-Dependent Lectin Pathway
Activation on Ex Vivo Xenoperfusion Samples
IF staining was performed on ex vivo xenoperfusion biopsy samples for the
deposition of MBL and its colocalization with IgM, C3b/c, C4b/c, and C6.
In brief, 20-Km-thick sections were cut, fixed on slide, and treated with TBS-
Triton X-100 for 15 min. Deposition of MBL and its colocalization with
complement proteins was assessed by using specific antibodies as mentioned
above. Stained slides were observed using fluorescence microscopy (DMI
4000B; Leica, Wetzlar, Germany).
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